Educational interventions targeted at patients within cardiac rehabilitation programmes should be made accessible to all the patients' environment, in the same way that cardiovascular prevention should not only involve individuals at risk, but also reach the whole population with a community-based, multidimensional approach. 1, 2 In this issue, the efficacy of combining an initial basic life support (BLS) training with 6-month hands-on rolling refreshers on the family of patients attending a cardiac rehabilitation programme with respect to usual care was compared. The study revealed that integrating BLS education in the cardiac rehabilitation training programme and regular retraining improved participants' retention of knowledge and skills in BLS compared with the control group.
Given the high mortality associated with out-ofhospital cardiac arrest, public BLS training with regular refreshers should be a priority for our society now.
Inhospital cardiac rehabilitation in heart failure
Administrative data represent a source of information to explore the impact of different healthcare policies, with specific advantages (high patient numbers, universal coverage, institutional ownership) and disadvantages (limited number of variables collected, lack of accuracy, differences in coding criteria across individuals and institutions, and changes in these criteria over time). 3, 4 A retrospective analysis from a healthcare administrative database involving more than 140,000 patients is presented in this issue. It showed reductions in mortality and hospital readmission rates between those heart failure patients undertaking inhospital cardiac rehabilitation versus no cardiac rehabilitation referral. After an acute episode of heart failure, the referral to inpatient cardiac rehabilitation or to the patient's own general practitioner was really entirely at the discretion of the treating physician. The inhospital cardiac rehabilitation programme was a multidisciplinary programme for a maximum period of 20 days and included clinical assistance, optimised medical or interventional treatment to relieve symptoms, appropriate cardiovascular risk evaluation, exercise training, education and counselling regarding risk reduction and lifestyle changes. Further work in this area should include robust healthcare economic analyses to examine the long-term feasibility of this approach.
Secondary prevention EUROASPIRE V: still poor implementation of recommended guidelines in coronary patients
The implementation of recommended targets in secondary prevention highlighted by the European Society of Cardiology guidelines has been repeatedly evaluated by the EUROASPIRE (European Action on Secondary and Primary Prevention by Intervention to Reduce Events) surveys. 5 In particular, EUROASPIRE V was performed to identify risk factors in coronary patients with and without diabetes, describing their management through lifestyle modifications and the use of drug therapies in order to provide an objective assessment of the implementation of current evidence-based cardiac prevention. It is observed that a large majority of coronary patients have unhealthy lifestyles in terms of smoking, diet and sedentary behaviour, which adversely impacts major cardiovascular risk factors. A majority did not achieve their blood pressure, lowdensity lipoprotein cholesterol and glucose targets.
Thus a greater adherence to the recommendations of the guidelines is needed and it requires specific secondary prevention programmes, including structured rehabilitation, useful also to reinforce patients' education on drug adherence and, as recently suggested, to optimise medical therapy.
Risk stratification
Testosterone, sex hormone-binding globulin and risk of cardiovascular events Low total testosterone levels have been shown to predict cardiovascular disease in relatively healthy cohorts drawn from the general population, but the link in a diseased study population is unclear, with some studies suggesting free testosterone as a more important predictor of mortality. 7 In this issue a study has demonstrated that sex hormone-binding globulin (SHBG), but not testosterone, was an independent predictor of cardiovascular events and all-cause mortality in a large population of disglycaemic men at high cardiovascular risk (n ¼ 5553, who participated in the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial).
However, whether this action is mediated through the role of SHBG on testosterone distribution or as a direct cardiovascular risk marker remains to be clarified.
Drug therapy Rivaroxaban and aspirin versus aspirin alone in vascular artery disease
Peripheral artery diseases constitute ominous clinical conditions with still a high burden of mortality due to poor management. 8, 9 On the other hand, the growing relevance of cost-effectiveness analysis in clinical practice has led to the publication of cost-effectiveness papers in clinical journals, also outside the borders of pharmacoeconomics journals. 10 This issue contains an Australian healthcare cost-effectiveness analysis regarding low-dose rivaroxaban in 1000 hypothetical individuals with peripheral artery disease or carotid artery disease, profiled on the COMPASS trial, using a Markov model. It demonstrates for the first time that low-dose rivaroxaban in addition to aspirin is costeffective (not just effective) in this patient population, and offers us a tool when dealing with public health stakeholders and decision-making bodies. The more we understand the mechanisms of cost-effectiveness analysis, the more we will be able to convince public health stakeholders that investing resources in costeffective treatments is a win-win choice both for the health of patients (our goal as clinicians) and for healthcare providers, in a medium-term perspective.
Antiplatelet therapy after an acute coronary syndrome
The beneficial impact of antiplatelet therapy after an acute coronary syndrome has been clearly demonstrated 11 and is highly recommended by current guidelines. An Italian administrative healthcare database including 25,129 patients discharged alive after an acute coronary syndrome investigated the implementation of such a recommendation in current practice. It showed that a high percentage (23%) of these patients were untreated with antiplatelet agents during the first month after their index event; 66% of subjects were prescribed an antiplatelet drug subsequently, while 7.7% did not receive any antiplatelet treatment during the whole of the following year. Yet these subjects presented a very high clinical complexity, as shown by the high rate of re-hospitalisation they experienced in the 12-month follow-up and by the high healthcare costs. In view of the prognostic improvement and the economic saving that could be achieved, it is desirable that these untreated patients with a severe clinical picture be better characterised in terms of contraindications to treatment, other comorbidities, concomitant therapies and the clinical setting of assistance. It is also desirable to implement initiatives to improve adherence to the recommendations of current guidelines, including structured rehabilitation programmes, useful also to reinforce patients' education on drug adherence and, as recently suggested, to exert a non-pharmacological platelet inhibition activity. 6 
Inflammation in coronary artery disease
There is now solid experimental, clinical and epidemiological evidence of a close association between inflammation and short and long-term cardiovascular outcomes. 12 Also, the increased risk of myocardial infarction after infections has been recognised for decades. 13 In this issue, in a study of more than 7600 patients with triple vessel disease followed for a median of 7.5 years, white blood cell count at admission was an independent predictor of death and major cardiovascular and cerebrovascular events during a mean 7.5-year follow-up. At multivariable analysis, increased monocytes and eosinophils and decreased lymphocytes were found to be independently associated with death. This report is important not only for the large sample size and the long follow-up, but also because it suggests a strong predictive value for subsequent cardiovascular events of the simplest laboratory test routinely performed in almost all patients admitted to the hospital.
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